文献速递冠心病

ISCHEMIA随机临床试验参与者基线特征与风险概况

Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2019-01-01

ISCHEMIA试验纳入8518例稳定缺血性心脏病(SIHD)患者,其中5179例随机分组;随机者中位年龄64岁,女性占22.6%,糖尿病占41.0%,多数存在多支冠状动脉病变。该文描述基线特征,未报告临床结局。

要点

  • 随机患者中位年龄64岁,糖尿病占41.0%,有心绞痛病史者占89.7%。
  • 负荷影像学随机者中,核心实验室判读缺血严重程度为重度者占44.8%。
  • 行冠状动脉CT血管造影的随机患者中,79.0%有多支冠状动脉病变。

核心结论

  • ISCHEMIA试验随机分组的是负荷试验显示中度或重度缺血的SIHD人群,其中多数存在多支冠状动脉病变。

研究设计与样本

  • ISCHEMIA为国际多中心随机临床试验,在38个国家的341个招募中心(320个随机中心)招募SIHD且负荷试验显示中度或重度缺血的患者。
  • 共纳入8518例患者,其中5179例被随机分组;多数参与者接受盲法冠状动脉CT血管造影并由核心实验室审核。

主要发现

  • 随机参与者中位年龄64岁,女性1168例(22.6%),非白人1726例(33.7%),西班牙裔748例(15.5%),糖尿病2122例(41.0%),有心绞痛病史4643例(89.7%)。
  • 负荷影像学随机者3909例中,核心实验室判读(3901例)缺血严重程度为重度1748例(44.8%)、中度1600例(41.0%)、轻度317例(8.1%)、无或不可判读236例(6.0%)。
  • 非影像学运动耐量试验(ETT)随机者1270例中,核心实验室判读(1266例)缺血严重程度为重度1051例(83.0%)、中度101例(8.0%)、轻度34例(2.7%)、无或不可判读80例(6.3%)。
  • 在5179例随机参与者中行冠状动脉CT血管造影的3912例里,79.0%(2679/3390)有多支冠状动脉病变,86.8%(3190/3677)有左前降支(LAD)狭窄,其中近段狭窄占46.8%(1749/3739)。
  • 行ETT的参与者相比行负荷影像学参与者,3支冠状动脉病变、LAD狭窄及近段LAD狭窄的频率更高。

临床怎么用

  • 该文仅描述ISCHEMIA试验随机人群的基线特征与风险概况,未报告临床结局,不能据此直接推导血运重建策略的疗效结论。

局限性

  • 本文未报告临床结局。
  • 排除原因包括核心实验室判定缺血不足、无保护左主干狭窄至少50%或不符合研究阻塞性冠状动脉疾病(CAD)标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: It is unknown whether coronary revascularization, when added to optimal medical therapy, improves prognosis in patients with stable ischemic heart disease (SIHD) at increased risk of cardiovascular events owing to moderate or severe ischemia. OBJECTIVE: To describe baseline characteristics of participants enrolled and randomized in the International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) trial and to evaluate whether qualification by stress imaging or nonimaging exercise tolerance test (ETT) influenced risk profiles. DESIGN, SETTING, AND PARTICIPANTS: The ISCHEMIA trial recruited patients with SIHD with moderate or severe ischemia on stress testing. Blinded coronary computed tomography angiography was performed in most participants and reviewed by a core laboratory to exclude left main stenosis of at least 50% or no obstructive coronary artery disease (CAD) (<50% for imaging stress test and <70% for ETT). The study included 341 enrolling sites (320 randomizing) in 38 countries and patients with SIHD and moderate or severe ischemia on stress testing. Data presented were extracted on December 17, 2018. MAIN OUTCOMES AND MEASURES: Enrolled, excluded, and randomized participants' baseline characteristics. No clinical outcomes are reported. RESULTS: A total of 8518 patients were enrolled, and 5179 were randomized. Common reasons for exclusion were core laboratory determination of insufficient ischemia, unprotected left main stenosis of at least 50%, or no stenosis that met study obstructive CAD criteria on study coronary computed tomography angiography. Randomized participants had a median age of 64 years, with 1168 women (22.6%), 1726 nonwhite participants (33.7%), 748 Hispanic participants (15.5%), 2122 with diabetes (41.0%), and 4643 with a history of angina (89.7%). Among the 3909 participants randomized after stress imaging, core laboratory assessment of ischemia severity (in 3901 participants) was severe in 1748 (44.8%), moderate in 1600 (41.0%), mild in 317 (8.1%) and none or uninterpretable in 236 (6.0%), Among the 1270 participants who were randomized after nonimaging ETT, core laboratory determination of ischemia severity (in 1266 participants) was severe (an eligibility criterion) in 1051 (83.0%), moderate in 101 (8.0%), mild in 34 (2.7%) and none or uninterpretable in 80 (6.3%). Among the 3912 of 5179 randomized participants who underwent coronary computed tomography angiography, 79.0% had multivessel CAD (n = 2679 of 3390) and 86.8% had left anterior descending (LAD) stenosis (n = 3190 of 3677) (proximal in 46.8% [n = 1749 of 3739]). Participants undergoing ETT had greater frequency of 3-vessel CAD, LAD, and proximal LAD stenosis than participants undergoing stress imaging. CONCLUSIONS AND RELEVANCE: The ISCHEMIA trial randomized an SIHD population with moderate or severe ischemia on stress testing, of whom most had multivessel CAD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01471522.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Hochman JS, Reynolds HR, Bangalore S, et al. Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. JAMA Cardiol. 2019. PMID: 30810700. doi:10.1001/jamacardio.2019.0014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。